Stephanie N Spohn1, Francesca Bianco2, Rachel B Scott3, Catherine M Keenan4, Alisha A Linton1, Conor H O'Neill5, Elena Bonora6, Michael Dicay7, Brigitte Lavoie1, Rebecca L Wilcox8, Wallace K MacNaughton7, Roberto De Giorgio6, Keith A Sharkey4, Gary M Mawe9. 1. Neurological Sciences, University of Vermont, Burlington, Vermont. 2. Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 3. Surgery, Danbury Hospital, Danbury, Connecticut. 4. Hotchkiss Brain Institute, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada; Snyder Institute for Chronic Diseases, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada. 5. Surgery, University of Vermont, Burlington, Vermont. 6. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 7. Snyder Institute for Chronic Diseases, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada. 8. Pathology, University of Vermont, Burlington, Vermont. 9. Neurological Sciences, University of Vermont, Burlington, Vermont. Electronic address: gary.mawe@uvm.edu.
Abstract
BACKGROUND & AIMS: The 5-hydroxytryptamine receptor 4 (5-HT4R or HTR4) is expressed in the colonic epithelium but little is known about its functions there. We examined whether activation of colonic epithelial 5-HT4R protects colons of mice from inflammation. METHODS: The 5-HT4R agonist tegaserod (1 mg/kg), the 5-HT4R antagonist GR113808 (1 mg/kg), or vehicle (control) were delivered by enema to wild-type or 5-HT4R knockout mice at the onset of, or during, active colitis, induced by administration of dextran sodium sulfate or trinitrobenzene sulfonic acid. Inflammation was measured using the colitis disease activity index and by histologic analysis of intestinal tissues. Epithelial proliferation, wound healing, and resistance to oxidative stress-induced apoptosis were assessed, as was colonic motility. RESULTS: Rectal administration of tegaserod reduced the severity of colitis compared with mice given vehicle, and accelerated recovery from active colitis. Rectal tegaserod did not improve colitis in 5-HT4R knockout mice, and intraperitoneally administered tegaserod did not protect wild-type mice from colitis. Tegaserod increased proliferation of crypt epithelial cells. Stimulation of 5-HT4R increased Caco-2 cell migration and reduced oxidative stress-induced apoptosis; these actions were blocked by co-administration of the 5-HT4R antagonist GR113808. In noninflamed colons of wild-type mice not receiving tegaserod, inhibition of 5-HT4Rs resulted in signs of colitis within 3 days. In these mice, epithelial proliferation decreased and bacterial translocation to the liver and spleen was detected. Daily administration of tegaserod increased motility in inflamed colons of guinea pigs and mice, whereas administration of GR113808 disrupted motility in animals without colitis. CONCLUSIONS: 5-HT4R activation maintains motility in healthy colons of mice and guinea pigs, and reduces inflammation in colons of mice with colitis. Agonists might be developed as treatments for patients with inflammatory bowel diseases.
BACKGROUND & AIMS: The 5-hydroxytryptamine receptor 4 (5-HT4R or HTR4) is expressed in the colonic epithelium but little is known about its functions there. We examined whether activation of colonic epithelial 5-HT4R protects colons of mice from inflammation. METHODS: The 5-HT4R agonist tegaserod (1 mg/kg), the 5-HT4R antagonist GR113808 (1 mg/kg), or vehicle (control) were delivered by enema to wild-type or 5-HT4R knockout mice at the onset of, or during, active colitis, induced by administration of dextran sodium sulfate or trinitrobenzene sulfonic acid. Inflammation was measured using the colitis disease activity index and by histologic analysis of intestinal tissues. Epithelial proliferation, wound healing, and resistance to oxidative stress-induced apoptosis were assessed, as was colonic motility. RESULTS: Rectal administration of tegaserod reduced the severity of colitis compared with mice given vehicle, and accelerated recovery from active colitis. Rectal tegaserod did not improve colitis in 5-HT4R knockout mice, and intraperitoneally administered tegaserod did not protect wild-type mice from colitis. Tegaserod increased proliferation of crypt epithelial cells. Stimulation of 5-HT4R increased Caco-2 cell migration and reduced oxidative stress-induced apoptosis; these actions were blocked by co-administration of the 5-HT4R antagonist GR113808. In noninflamed colons of wild-type mice not receiving tegaserod, inhibition of 5-HT4Rs resulted in signs of colitis within 3 days. In these mice, epithelial proliferation decreased and bacterial translocation to the liver and spleen was detected. Daily administration of tegaserod increased motility in inflamed colons of guinea pigs and mice, whereas administration of GR113808 disrupted motility in animals without colitis. CONCLUSIONS:5-HT4R activation maintains motility in healthy colons of mice and guinea pigs, and reduces inflammation in colons of mice with colitis. Agonists might be developed as treatments for patients with inflammatory bowel diseases.
Authors: Yasmin Nasser; Ester Fernandez; Catherine M Keenan; Winnie Ho; Lorraine D Oland; Lee Anne Tibbles; Michael Schemann; Wallace K MacNaughton; Anne Rühl; Keith A Sharkey Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-06-22 Impact factor: 4.052
Authors: Maria Van der Sluis; Barbara A E De Koning; Adrianus C J M De Bruijn; Anna Velcich; Jules P P Meijerink; Johannes B Van Goudoever; Hans A Büller; Jan Dekker; Isabelle Van Seuningen; Ingrid B Renes; Alexandra W C Einerhand Journal: Gastroenterology Date: 2006-07 Impact factor: 22.682
Authors: Jane A Roberts; Leonie Durnin; Keith A Sharkey; Violeta N Mutafova-Yambolieva; Gary M Mawe Journal: J Physiol Date: 2013-06-03 Impact factor: 5.182
Authors: Gregory M Holmes; Charles H Hubscher; Andrei Krassioukov; Lyn B Jakeman; Naomi Kleitman Journal: J Spinal Cord Med Date: 2019-09-26 Impact factor: 1.985
Authors: B Lavoie; J A Roberts; M M Haag; S N Spohn; K G Margolis; K A Sharkey; J B Lian; G M Mawe Journal: Pharmacol Res Date: 2018-07-17 Impact factor: 7.658
Authors: John R Konen; Melody M Haag; Daria Guseva; Molly Hurd; Alisha A Linton; Brigitte Lavoie; Colleen B Kerrigan; Emily Joyce; Stephan C Bischoff; Steve Swann; Luana Griffin; Jun Matsukawa; Matthew D Falk; Tony S Gibson; Grant W Hennig; Jill Wykosky; Gary M Mawe Journal: Neurogastroenterol Motil Date: 2020-11-12 Impact factor: 3.598